Craig A. Wheeler
President and Chief Executive Officer
Jim Anderson, Ph.D.
Senior Vice President, Pharmaceutical Sciences
Senior Vice President, Human Resources
Ian D. Fier
Senior Vice President, Program and Project Management
Ganesh V. Kaundinya, Ph.D.
Co-Founder, Chief Scientific Officer and Senior Vice President, Research
Young Kwon, Ph.D.
Senior Vice President, Corporate Development and Strategy
Anthony Manning, Ph.D.
Senior Vice President, Research
Bruce A. Leicher
General Counsel, Senior Vice President and Secretary
Chief Operating Officer
Jim Roach, M.D.
Chief Medical Officer and Senior Vice President, Development
Richard P. Shea
Chief Financial Officer and Senior Vice President
Mr. Wheeler joined Momenta as CEO in September of 2006. He led the company through the launch of its first complex drug products, including the first generic versions of LOVENOX® and once-daily COPAXONE®. He has overseen the company’s growth into the diversified business it is today. In 2011, he was an E&Y Entrepreneur of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta the number one company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr. Wheeler was President of Chiron BioPharmaceuticals where during his five-year tenure the pharmaceutical division’s global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group’s health care practice and worked extensively in the health care sector. He began his career at Merck’s MSDRL research unit. Mr. Wheeler previously served as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. He also served as GPhA’s Chairman of the Board of Directors from 2014 to February 2016.
Dr. Anderson joined Momenta Pharmaceuticals in March of 2007. He is responsible for the establishment of manufacturing processes and associated controls, supply of clinical materials, transfer of commercial processes to external CMO partners, and preparation of CMC regulatory submissions for all of Momenta’s products that are in development. Dr. Anderson initially joined Momenta as the head of the Analytical Development organization. Prior to Momenta, he was the Director of Pharmacy and Analytical Development at Bristol-Myers Squibb Medical Imaging, where he led project teams for new drug product programs. In total, Dr. Anderson has approximately 25 years of CMC development experience.
Ms. Beltramello joined Momenta in October of 2007. She was previously the Chief Human Resources Officer at Multiplan, a provider of health care cost management solutions with over 2,000 employees conducting business in all fifty states. In this role, she was responsible for all human resource operations, including strategy, policies and program development. Prior to joining Multiplan, she held senior human resources roles at Private Healthcare Systems, Inc., Oxford Global Resources, Inc., and Randstad North America.
Mr. Fier joined Momenta in October of 2002. He was previously Vice President of Clinical Affairs at BioTransplant Inc. where he led a clinical development group responsible for the development and commercialization of both antibody-based therapeutics and medical devices. Prior to that, he held positions in product development and project management at Hoechst-Roussel (now Sanofi Aventis), Astra USA and The Medicines Company and was involved with the development and launch of several successful products. Mr. Fier received his BS from Tufts University and a MBA in Heath Care Management from Boston University.
Dr. Kaundinya is one of Momenta's founders. Since inception, Dr. Kaundinya has played a key role in defining the business and scientific strategy and in building and leading the research organization. Prior to founding Momenta, Dr. Kaundinya was a member of the MIT faculty where he pioneered research in the areas of analytical techniques for complex molecules and extracellular matrix regulation of cell biology. He also served as the Director of Bioinformatics for the Consortium for Functional Glycomics, a multi-milliondollar NIH initiative to study the role of complex sugars in biology.
Dr. Kwon joined Momenta in January of 2011. At Momenta, he is responsible for driving business and corporate development strategy aimed at achieving Momenta’s corporate objectives. These objectives include further developing our biosimilars and novel drug businesses through strategic transactions like those with Baxter Healthcare, Virdante Pharmaceuticals and others. He was previously Senior Director of Business Development at Biogen Idec, where he led corporate development activities, including evaluation of mergers and acquisitions, joint ventures and other strategic transactions. Prior to that, he identified and invested in early-stage life science companies at Advanced Technology Ventures. He has co-authored numerous peer-reviewed publications in the area of neurobiology.
Mr. Leicher joined Momenta in July of 2008. He was previously Senior Vice President and General Counsel at Altus Pharmaceuticals Inc. and also served as General Counsel and in senior legal positions at Antigenics Inc., Millennium Pharmaceuticals, Inc., Curis, Inc., Genetics Institute, Inc., and Wyeth. Mr. Leicher brings significant legal expertise in research and product development, product commercialization and launch, corporate finance and partnering transactions, intellectual property law and licensing, corporate governance and litigation. In private practice, he served as the Co-Chair of the Life Sciences Practice Group at Hill and Barlow and was an attorney at Hale and Dorr and Butler and Binion.
Dr. Manning joined Momenta in January 2013. He is responsible for research and driving the discovery of novel products. Since joining Momenta, his teams have advanced three novel autoimmune drugs (M281, M230 and hsIVIg) into development and implemented a research engine to discover novel personalized therapies based on patient biocharacterization. Prior to Momenta, Dr. Manning was Vice President and Head of Immunology Research for Biogen Idec, Inc. Before that, he was Vice President and Global Head of Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals. Dr. Manning holds a PhD from the University of Otago, New Zealand, and has authored more than 100 peer-reviewed publications and patents in the fields of signal transduction, autoimmune diseases and drug discovery.
Mr. Ottmer joined Momenta in December 2015 as Chief Operating Officer. At Momenta, he is responsible for the operational management of product development, research, clinical development, pharmaceutical sciences and commercial activities. He previously served as Senior Vice President, Strategy & Emerging Businesses at Biogen, Inc. Mr. Ottmer joined Biogen in 1999 and held positions of increasing responsibility and breadth including: Head of Tysabri Business, Chief of Staff to the CEO, President of Syntonix Pharmaceuticals, Inc. (a wholly owned subsidiary of Biogen), and Vice President, Global Operations. Prior to Biogen, he served as a management consultant with A.T. Kearney.
Dr. Roach joined Momenta in February of 2008. He is responsible for preclinical and clinical development and regulatory affairs. Previously he was the Senior Vice President of Medical Affairs at Sepracor. He has also held senior clinical research and/or medical affairs positions at Millennium Pharmaceuticals, LeukoSite, Medical and Technical Research Associates and Astra USA. Dr. Roach is Board Certified in Internal Medicine and Pulmonary Disease. He has been affiliated with the Pulmonary and Critical Care Medicine Division of Brigham and Women’s Hospital since 1993 and is an Assistant Professor of Medicine, Part-time, at Harvard Medical School. Dr. Roach is also a Fellow of the American College of Physicians and the American College of Chest Physicians.
Mr. Shea joined Momenta in October of 2003. During his tenure Momenta has raised over $380 million, including the company’s IPO in June 2004. He was previously Chief Operating Officer, Chief Financial Officer and Treasurer at Variagenics, Inc., a pharmacogenomics company, where he assisted in raising over $120 million, including their IPO in July 2000. While at Variagenics, Mr. Shea was responsible for Finance, Legal, Investor Relations, Human Resources and Operations. Prior to this, Mr. Shea was Vice President of Finance at Genetics Institute, Inc. (now Pfizer), and a Senior Manager at PricewaterhouseCoopers.
Last Updated 4/1/2016